Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Coca
Coca (Erythroxylum coca Lam., Erythroxylaceae) is a flowering shrub native to the Andes whose leaves contain the stimulant alkaloid cocaine. Cocaine determines the pharmacological character of every coca preparation. It blocks the brain's dopamine recycling system, flooding reward circuits and producing the plant's stimulant and euphoric effects.[1]
Coca (Erythroxylum coca Lam., Erythroxylaceae) is a flowering shrub native to the western Andes whose leaves contain the tropane alkaloid cocaine. Cocaine acts as a triple monoamine reuptake inhibitor, blocking the dopamine, norepinephrine, and serotonin transporters.[1] Dopamine transporter blockade in mesolimbic circuits drives the plant's reinforcing and euphoriant properties, while voltage-gated sodium channel blockade produces local anesthetic effects and contributes to cardiac toxicity.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Archaeological evidence places Andean coca use at least 8,000 years before present.[2] Cocaine was first isolated from the leaf in 1860, setting off a wave of pharmaceutical applications and eventually tight international restriction. Today both coca leaf and cocaine are scheduled under the 1961 UN Single Convention, though Bolivia and Peru maintain legal frameworks for traditional leaf use.[3]
Subjective effects include stimulation, euphoria, appetite suppression, increased confidence, and local numbness in the mouth and throat. The experience varies enormously by preparation: leaf chewing produces mild, sustained alertness comparable to strong tea, while smoked cocaine delivers a brief, overwhelming rush followed by rapid craving. Anxiety, paranoia, racing heart, and a dysphoric crash are characteristic unsought effects, particularly with refined preparations.
Cocaine carries significant abuse liability and cardiovascular toxicity — including risk of heart attack, arrhythmia, and sudden cardiac death.[4] The illicit supply is heavily contaminated: levamisole adulterates an estimated 69–80% of US cocaine, causing blood disorders independent of cocaine's own effects,[5] and fentanyl contamination is increasingly common. No approved treatment for cocaine use disorder exists as of 2026,[6] and controlled data on whole-leaf preparations remain sparse.
History[edit]
Traditional and historical use
Indigenous peoples of the Andes have cultivated and consumed coca for at least 8,000 years.[2] Traditional preparation involves placing fresh or dried leaves in the cheek alongside an alkaline additive — calcium hydroxide, plant ash, or sodium bicarbonate — which raises buccal pH and promotes cocaine absorption.[7] Documented uses include stamina during physical labor, hunger and fatigue suppression, altitude sickness relief, mild analgesia, and ceremonial purposes.[7][2]
Western discovery and pharmaceutical development
Albert Niemann first isolated cocaine from coca leaves in 1860 at the University of Göttingen, noting its anesthetic effect on his own tongue.[8] Carl Koller demonstrated cocaine as a topical anesthetic for eye surgery in 1884, transforming the field.[8] Coca-Cola launched in 1886 using coca extract; the product was decocainized by 1903.[7]
Modern era
The Harrison Narcotics Tax Act (1914) restricted non-medical cocaine in the United States. The 1961 UN Single Convention placed both coca leaf and cocaine on Schedule I — an unusual dual scheduling that explicitly controls the plant alongside its isolated alkaloid. In October 2025, the WHO Expert Committee completed a comprehensive review and recommended maintaining Schedule I classification, while acknowledging the low public health risk of traditional consumption and the cultural significance of coca to indigenous peoples.[3]
Botanical Overview[edit]
Coca belongs to the genus Erythroxylum and the family Erythroxylaceae — a small family of tropical and subtropical shrubs. Two primary cultivated species are recognized: E. coca (Huánuco coca) and E. novogranatense (Colombian coca). Each has varieties that differ in alkaloid content and geographic distribution.
Coca is native to the eastern Andean slopes of Peru and Bolivia, thriving in warm, humid montane forest between roughly 500 and 2,000 meters elevation. Bolivia, Peru, and Colombia account for virtually all current cultivation. The plant is not known to persist in the wild independent of human cultivation.
The shrub grows 1–3 meters tall with slender, oval leaves 4–8 cm long. Each leaf carries two faint lines running parallel to the central vein — a diagnostic feature distinguishing Erythroxylum from similar-looking shrubs. Small yellowish-white flowers produce red drupes approximately 1 cm in length.
Alkaloid Profile[edit]
Cocaine is the dominant active alkaloid in coca leaf, present at 0.2–1.0% of dry weight. It blocks the brain's dopamine, norepinephrine, and serotonin recycling systems simultaneously, with an additional local anesthetic effect produced by sodium channel blockade.[1][9] The pharmacological character of coca preparations is determined almost entirely by cocaine itself.
Several minor alkaloids are present but poorly understood. Cinnamoylcocaine and its isomers are structurally related to cocaine but pharmacologically weaker. Truxillines are dimeric cocaine derivatives present in trace amounts. Hygrine, a separate alkaloid class, lacks meaningful central nervous system activity. Traditional users sometimes attribute a qualitative difference between whole-leaf coca and purified cocaine to this full alkaloid matrix — but no controlled study has demonstrated that effect.
E. novogranatense tends toward lower cocaine content with a proportionally higher fraction of minor alkaloids than E. coca. Harvest season, soil conditions, altitude, and drying method all influence the final alkaloid profile of available leaf material.
Neuroscience[edit]
Where it acts
Cocaine's psychoactive effects arise from blocking dopamine recycling in the brain's mesolimbic mesolimbic pathway — the projection from the ventral tegmental area to the nucleus accumbens.[1] This floods synapses with dopamine, producing euphoria and reinforcing the behavior. Cocaine also blocks norepinephrine recycling, driving cardiovascular arousal and heightened alertness; sodium channel blockade produces the local anesthetic effect and creates arrhythmia risk.[9]
What it changes
Repeated cocaine use triggers synaptic changes in the reward pathway that drive compulsive use and increase relapse vulnerability.[2] Tolerance to euphoria develops rapidly, while sensitivity to psychomotor effects and psychosis risk increases — chronic users chase a diminishing high while facing escalating psychiatric danger. With prolonged use, cocaine also speeds up its own liver metabolism,[10] generating a more toxic byproduct called norcocaine.[11]
No neuroimaging studies using coca leaf preparations as administered — rather than refined cocaine — have been published. The contribution of minor coca alkaloids (cinnamoylcocaine, truxillines, hygrine) to whole-leaf pharmacology is unknown. Preparation-specific pharmacokinetics for traditional coca leaf chewing and tea infusion remain poorly characterized in controlled human studies.
Subjective Effects[edit]
Coca preparations span a wide experiential range determined almost entirely by preparation method. Traditional leaf chewing produces subtle, sustained alertness with mild appetite suppression and gentle mouth numbness — qualitatively closer to a strong cup of tea than to the intense euphoria associated with refined cocaine. Smoked or injected cocaine delivers brief, overwhelming euphoria followed almost immediately by craving and the drive to redose.
In terms of stimulant intensity, coca leaf chewing sits somewhere between caffeine and low-dose amphetamine. Refined cocaine administered intranasally or by inhalation is closer to methamphetamine in reinforcement potency and addiction trajectory — though its effects are substantially shorter-lived and its cardiovascular risk profile is distinct.
Archaeological evidence places Andean coca use at least 8,000 years before present.[3] Albert Niemann's 1860 isolation of cocaine from the leaf catalyzed rapid pharmaceutical adoption — most notably Carl Koller's 1884 demonstration of topical cocaine anesthesia — followed by international regulatory restriction.[4] In 2025, the WHO Expert Committee recommended maintaining Schedule I classification under the 1961 UN Single Convention while acknowledging the low public health risk of traditional leaf consumption.[5]
Subjective effects include stimulation, euphoria, appetite suppression, increased confidence, and local anesthesia. The experiential character varies dramatically by preparation — leaf chewing produces mild sustained alertness comparable to strong tea, while smoked cocaine delivers intense brief euphoria followed by rapid-onset craving and compulsive redosing. Anxiety, paranoia, and cardiovascular stress are common unsought effects, particularly at higher doses.
Cocaine carries significant abuse liability and cardiovascular toxicity including myocardial infarction, arrhythmias, and sudden cardiac death.[6] Rapid mesolimbic dopamine reinforcement drives psychological dependence, while the illicit supply is heavily contaminated — levamisole adulterates an estimated 69–80% of US cocaine, introducing independent hematological toxicity.[7] No approved pharmacotherapy for cocaine use disorder exists as of 2026,[8] and controlled clinical data specific to whole-leaf preparations remain sparse.
History[edit]
Traditional and historical use
Indigenous peoples of the Andes have cultivated and consumed coca for millennia, with archaeological evidence placing use at least 8,000 years before present.[3] The two primary cultivated species — E. coca and E. novogranatense — were selected for their tropane alkaloid content before formal domestication of either species.[3] Traditional preparation involves chewing fresh leaves with an alkaline additive — calcium hydroxide, sodium bicarbonate, or llipta (plant ash) — to raise buccal pH and facilitate cocaine absorption.[9]
Documented traditional applications include stamina enhancement during physical labor, hunger and fatigue suppression, altitude sickness mitigation, mild analgesia, and ceremonial use.[9][3] These accounts derive from ethnographic and anthropological documentation rather than controlled clinical studies.
Western discovery and pharmaceutical development
Spanish chroniclers documented coca use in the 16th century, though knowledge of its stimulant properties spread slowly in Europe. Albert Niemann first isolated cocaine from coca leaves in 1860 at the University of Göttingen, noting the anesthetic effect on his tongue in his dissertation.[4] Richard Willstätter established cocaine's correct molecular structure in 1898.citation needed
The isolation catalyzed rapid pharmaceutical adoption. Carl Koller demonstrated cocaine as a topical ophthalmic anesthetic in 1884, revolutionizing eye surgery.[4] William Halsted pioneered nerve block anesthesia using the compound but developed dependence in the process. Commercial applications followed: Coca-Cola launched in 1886 using coca extract, though the product was decocainized by 1903.[9]
Modern era
The Harrison Narcotics Tax Act (1914) restricted non-medical cocaine distribution in the United States. The 1961 UN Single Convention on Narcotic Drugs placed both coca leaf and cocaine on Schedule I, and the 1988 Convention reinforced controls on cocaine precursors. Bolivia temporarily withdrew from the 1961 Convention in 2012 and reacceded in 2013 with an explicit reservation permitting traditional coca leaf chewing.citation needed
In October 2025, the WHO Expert Committee on Drug Dependence completed a comprehensive critical review of coca leaf and recommended maintaining Schedule I classification, while acknowledging the low public health risk of traditional consumption and the cultural significance of coca to indigenous peoples.[5]
Botanical Overview[edit]
Erythroxylum coca Lam. belongs to the family Erythroxylaceae, a small family of tropical and subtropical shrubs and trees. The genus name derives from Greek erythros (red) and xylon (wood), referring to the reddish heartwood characteristic of the group. Two primary cultivated species are recognized: E. coca (Huánuco coca) and E. novogranatense (Colombian coca), each with recognized varieties that differ in alkaloid content and geographic distribution.
Coca is native to the eastern slopes of the Andes in Peru and Bolivia, thriving in warm, humid montane forest between roughly 500 and 2,000 meters elevation. Bolivia, Peru, and Colombia account for virtually all current cultivation. The plant is not known to persist in the wild independent of human cultivation in any significant population.
The shrub grows 1–3 meters tall with slender, oval leaves 4–8 cm long. Each leaf bears two faint longitudinal lines parallel to the midrib — a diagnostic feature distinguishing Erythroxylum from superficially similar shrubs. Small yellowish-white flowers produce red drupes approximately 1 cm in length.
Leaves are harvested by hand two to four times per year, sun-dried, and either consumed directly (chewing, tea infusion) or processed into refined alkaloid preparations. Drying method influences alkaloid retention: traditional sun-drying preserves the full alkaloid profile, while industrial extraction targets cocaine specifically. Potency varies across cultivars, harvest batches, altitude, and seasonal conditions.
Alkaloid Profile[edit]
Cocaine is the dominant pharmacologically active alkaloid in coca, present at 0.2–1.0% of leaf dry weight. It acts as a non-selective monoamine reuptake inhibitor — blocking the dopamine, norepinephrine, and serotonin transporters — with additional voltage-gated sodium channel blockade that produces local anesthetic effects.[1][2] Cocaine content varies across cultivars, growing conditions, altitude, and harvest timing, with E. coca var. coca typically yielding the highest concentrations.
Unlike cannabis or kratom, coca has no well-characterized entourage effect in which minor alkaloids meaningfully modulate the dominant alkaloid's activity. Traditional users sometimes attribute a qualitative difference between whole-leaf coca and purified cocaine to the full alkaloid matrix, but this has not been demonstrated in any controlled study. The pharmacological character of coca preparations is shaped almost entirely by cocaine itself.
Several minor tropane and non-tropane alkaloids are present in the leaf. Cinnamoylcocaine and its isomers are structurally related to cocaine but pharmacologically weaker. Truxillines (alpha- and beta-truxilline) are dimeric cocaine derivatives present in trace amounts. Hygrine, a non-tropane pyrrolidine alkaloid, is present at variable concentrations and lacks significant central nervous system activity. The relative contribution of these minor alkaloids to the overall pharmacological profile of whole-leaf preparations remains unknown.
Alkaloid concentrations vary across the two cultivated species and their varieties. E. novogranatense tends toward lower cocaine content with a proportionally higher fraction of minor alkaloids compared to E. coca. Harvest season, soil conditions, and drying method all influence the final alkaloid profile of commercially available leaf material.
Neuroscience[edit]
Where it acts
Cocaine's principal psychoactive effects arise from blockade of the DAT in the mesolimbic pathway — the projection from the ventral tegmental area to the nucleus accumbens.[1] The resulting surge of synaptic dopamine produces euphoria and behavioral reinforcement. A proposed mechanistic refinement suggests cocaine may reverse transporter direction, actively pumping dopamine into the synapse rather than simply blocking reuptake — potentially explaining why cocaine produces greater euphoria than other dopamine reuptake inhibitors of comparable binding strength.[1]
Concurrent NET blockade drives cardiovascular activation and heightened arousal. Serotonin transporter blockade, the weakest of the three, contributes to mood elevation. Sodium channel blockade underlies the local anesthetic effect and the arrhythmogenic potential that contributes to cocaine-associated sudden cardiac death.[2]
What it changes
With repeated cocaine exposure, glutamatergic and opioidergic plasticity at nucleus accumbens synapses contributes to compulsive use and relapse vulnerability.[3] Tolerance to euphoriant effects develops rapidly, while sensitization — not tolerance — occurs for psychomotor activation and psychosis risk. This explains why chronic users chase a diminishing high while facing escalating psychiatric danger.
Cocaine induces its own hepatic CYP metabolism with chronic use,[10] increasing production of norcocaine — an active metabolite with greater toxicity than the parent compound.[11]
No neuroimaging studies using coca leaf preparations as administered — rather than refined cocaine — have been published. The contribution of minor coca alkaloids (cinnamoylcocaine, truxillines, hygrine) to whole-leaf pharmacology is unknown. Preparation-specific pharmacokinetics for traditional coca leaf chewing and tea infusion remain poorly characterized in controlled human studies.
Subjective Effects[edit]
Coca preparations span a remarkably wide experiential range determined almost entirely by preparation method. Traditional leaf chewing produces subtle, sustained alertness with mild analgesia and appetite suppression — qualitatively closer to a strong cup of tea than to the intense euphoria associated with refined cocaine. Smoked and intravenous cocaine deliver brief, overwhelming euphoria followed by rapid-onset craving that drives compulsive redosing. Set and setting modulate the experience but remain secondary to the pharmacokinetic profile determined by preparation.
Coca leaf chewing occupies a pharmacological position between caffeine and low-dose amphetamine in terms of stimulant intensity and duration. Refined cocaine administered intranasally or by inhalation is more comparable to methamphetamine in reinforcement potency and addiction trajectory, though with substantially shorter duration of action and a distinct cardiovascular risk profile.
Effect Grid
Clear stimulation and cognitive euphoria with pronounced confidence and sociability enhancement. Communication enhancement is evident — speech flows easily, talkativeness increases. Focus enhancement and thought acceleration are noticeable. Motivation enhancement drives purposeful activity. Ego inflation produces feelings of competence and grandiosity.
Appetite suppression is pronounced. Heart rate and blood pressure increase measurably. Pupil dilation is visible. Vasoconstriction produces nasal numbness (intranasal) and peripheral cooling. Restlessness and mild bruxism may emerge toward the end of the experience. Insomnia is likely if taken within several hours of intended sleep.
For intranasal cocaine HCl, common doses are 20-75 mg. Coca leaf chewing at 20-60 g with alkaline additive delivers approximately 10-30 mg cocaine. Compulsive redosing urge begins to emerge at this tier, particularly with faster routes of administration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tingling / electric sensations · Dry mouth · Heart rate perception changes · Pupil dilation · Body high · Insomnia · Muscle tension · Restlessness · Salivation · Motor control enhancement · Excessive sweating · Nausea · Nausea suppression · Respiratory stimulation · Sexual arousal enhancement · Bruxism · Vomiting
Body high · Insomnia · Muscle tension · Restlessness · Salivation · Motor control enhancement · Excessive sweating · Nausea · Nausea suppression · Respiratory stimulation · Sexual arousal enhancement · Bruxism · Vomiting
Motivation enhancement · Analysis enhancement · Cognitive flexibility · Language enhancement · Memory enhancement · Creativity enhancement
Memory enhancement · Creativity enhancement
Ego inflation · Flow state
Timeline · by preparation
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Critical
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamines
Toxicity
Cocaine is the most frequent cause of drug-related death reported by US medical examiners.[12] The primary risk is cardiovascular: frequent users face a 7-fold higher risk of heart attack.[4][9][13] Cocaine narrows coronary arteries, promotes clot formation, and disrupts heart rhythm — any of which can cause sudden death.
Chronic use generates norcocaine, a liver-toxic byproduct that causes liver cell death and fatty change.[14] Multi-organ failure combining muscle breakdown, kidney injury, and liver damage is documented.[15]
Smoked cocaine can trigger "crack lung" — acute respiratory distress with fever, blood in the cough, and lung bleeding within 48 hours.[16] Both ischemic and hemorrhagic stroke are documented; reversible cerebral vasoconstriction has been reported even after coca tea at high altitude.[17]
Levamisole contaminates an estimated 69–80% of illicit US cocaine,[5][18] causing dangerously low white blood cell counts and blood vessel inflammation. Fentanyl contamination is increasingly common and introduces opioid overdose risk separate from cocaine's own toxicity.
Psychological Risks
Paranoid delusions, hallucinations, and thought disorganization can emerge with cocaine use. Prevalence reaches 86.5% in some clinical populations.[19] High cumulative dose, smoked or intravenous route, cannabis co-use, and pre-existing ADHD all increase the risk.[19] Repeated use does not build tolerance to psychosis — it progressively lowers the threshold for psychotic symptoms. Anxiety, panic, grandiosity, and impaired judgment occur across all preparations at sufficient doses.
Tolerance & Dependence
Tolerance to euphoria develops rapidly. Simultaneously, sensitivity to psychomotor effects and psychosis risk increases — the opposite of tolerance. Dependence is primarily psychological, driven by mesolimbic dopamine reinforcement, though physical dependence is also present. Withdrawal follows a three-phase pattern[20]:
- Phase 1 — Crash (hours to 4 days): dysphoria, fatigue, hypersomnia with REM rebound effect, appetite enhancement, temporarily reduced craving.
- Phase 2 — Withdrawal (1–10 weeks): anhedonia, anxiety, sleep disturbance, intense cue-triggered cravings; highest relapse risk period.
- Phase 3 — Extinction (months to years): Gradual normalization; intermittent cue-triggered cravings persist.[20]
Recovery resources, crisis lines, and support pathways → View all
Drug Interactions
Ethanol (alcohol): The most clinically significant interaction. Liver enzymes convert cocaine and alcohol together into cocaethylene — more toxic than cocaine itself and longer-lasting.[21][22][23] Cocaethylene yield varies by route: oral (34%) > intravenous (24%) > smoked (18%).[21]
Beta-adrenergic blockers: Contraindicated. Blocking beta receptors leaves cocaine's arterial constriction effects unopposed, producing severe hypertension and coronary vasospasm.
MAO inhibitors: Risk of severe blood pressure crisis and serotonin overload via amplified monoamine activity.safety citation needed
CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): May raise cocaine blood levels by slowing its clearance while reducing norcocaine formation.[11]safety citation needed
Tricyclic antidepressants: Additive cardiovascular toxicity from combined sodium channel blockade and norepinephrine buildup.safety citation needed
Contraindications
Pregnancy is an absolute contraindication — associated with placental abruption and fetal brain development effects.[24] Pre-existing cardiovascular disease is an absolute contraindication; the risk of heart attack and sudden death rises dramatically.[4] Concurrent beta-blocker therapy is absolutely contraindicated. Hepatic impairment, concurrent MAOI or tricyclic antidepressant therapy, and personal or family history of schizophrenia or psychosis are relative contraindications.[19]
Preparations[edit]
Coca leaf chewing (traditional)
Coca leaf chewing is the oldest and mildest preparation. Fresh or dried leaves (20–60 g per session) are held in the cheek with an alkaline additive — calcium hydroxide, sodium bicarbonate, or llipta (plant ash) — which raises buccal pH and promotes cocaine absorption.[7] Onset: 15–45 minutes. Peak: 60–90 minutes. Duration: 2–4 hours. Effects are mild sustained alertness, appetite suppression, and gentle analgesia. Accumulation from repeated chewing is unlikely given the slow absorption rate.[25]
Coca tea (mate de coca)
Coca tea is prepared by steeping dried leaves in hot water for 5–15 minutes. Onset: 30–60 minutes. Duration: 2–4 hours. Oral bioavailability is approximately 32–45%.[26] Effects are comparable to leaf chewing — mild stimulation and alertness. Legal and widely consumed in Bolivia, Peru, and parts of Argentina.
Cocaine hydrochloride (intranasal)
Intranasal cocaine (insufflation of cocaine hydrochloride powder) produces onset in 3–5 minutes, peak effects at 15–30 minutes, and duration of 45–90 minutes. Bioavailability is approximately 60–75%.[25] Effects are markedly more intense than leaf preparations: strong euphoria, heightened confidence, talkativeness, and a pronounced crash that drives redosing. Repeated use causes nasal mucosal damage.
Smoked cocaine (freebase / crack)
Smoked cocaine (freebase or crack) produces onset in under one minute. Peak: 3–5 minutes. Duration: 10–20 minutes. Bioavailability is approximately 70–80%. The extreme brevity of effects produces the strongest compulsive redosing drive of any non-intravenous preparation. Pulmonary toxicity, including "crack lung" syndrome, is specific to this route.[16]
Intravenous cocaine
Intravenous cocaine produces onset within seconds, peaks at 1–2 minutes, and lasts 20–40 minutes with 100% bioavailability. This route carries the highest risk of acute cardiovascular events and introduces infection risk from injection practices. Compulsive redosing frequency is comparable to smoked cocaine.
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Harm Reduction[edit]
Forms & Identification
Lab testing is the only reliable way to determine the purity of refined cocaine. The illicit supply is extensively adulterated — levamisole contaminates the majority of US cocaine, and fentanyl is increasingly present. Fentanyl test strips detect fentanyl but not all synthetic opioid analogs. Reagent testing (Scott/cobalt thiocyanate) confirms cocaine is present but cannot quantify purity or identify all adulterants.
For coca leaf products purchased in Andean countries, adulterant risk is substantially lower, but standardized potency testing is not available. Alkaloid content varies across batches and cultivars — dose conservatively when switching sources.
Guidelines
- Start with the lowest effective amount and wait for full onset before considering redosing — onset varies dramatically by preparation (leaf chewing: 15–45 min; intranasal: 3–5 min)
- Pre-measure amounts before a session to limit compulsive redosing; the rapid offset of smoked and intranasal cocaine drives repeated use
- Test all refined cocaine products with fentanyl test strips before use
- Use in the presence of others who can recognize and respond to medical emergencies
- Stay hydrated and eat before use — cocaine suppresses appetite and masks dehydration
- Monitor heart rate; stop immediately and seek medical attention if chest pain, palpitations, or difficulty breathing occur
- Alternate nostrils and rinse with saline after intranasal use to reduce mucosal damage
- Avoid binge patterns; set a firm time limit for sessions
Set & Setting
The setting significantly influences risk. Social environments that normalize compulsive redosing — common with intranasal and smoked preparations — amplify dependence risk. Using alone increases the danger of unwitnessed cardiac events or psychotic episodes.
A sober companion who can recognize cardiac distress or psychotic symptoms and call emergency services reduces acute mortality risk. For traditional coca leaf preparations, risk is substantially lower but not zero — reversible cerebral vasoconstriction has been reported with coca tea at high altitude.
Aftercare & integration. The post-cocaine crash brings dysphoria, fatigue, and appetite enhancement. For intranasal and smoked preparations, the crash can begin within minutes of last use and persist for hours to days depending on session length and cumulative dose.
Prioritize sleep, hydration, and nutrition during the crash period. Hypersomnia is expected and should not be resisted. Avoid using other stimulants to counteract post-cocaine fatigue — this extends recovery time and increases cardiovascular strain. For regular users, the withdrawal period (1–10 weeks) involves anhedonia, anxiety, and intense cue-triggered cravings. Identifying and avoiding environmental cues associated with prior use reduces relapse risk during this vulnerable window.
Recovery & Support
No FDA-approved pharmacotherapy for cocaine use disorder exists as of 2026. Evidence-supported treatments include cognitive behavioral therapy (CBT), contingency management (CM), and integrated treatment of comorbid psychiatric conditions.
For individuals seeking to reduce or stop cocaine use:
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7 referral service)
- Cocaine Anonymous: peer-support fellowship modeled on the 12-step framework
- Outpatient CBT and contingency management programs are available through most addiction treatment centers
Abrupt cessation of cocaine is medically safe, though psychologically difficult. The highest relapse risk occurs during weeks 1–10 after last use, when cue-triggered cravings are most intense. Professional support during this period significantly improves outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain, pressure, or tightness
- Irregular or racing heartbeat
- Difficulty breathing
- Severe paranoia, hallucinations, or psychotic behavior
- Seizures or loss of consciousness
- Blue lips or extremities
- Hyperthermia (hot, dry skin)
Immediate steps:
- 1. Call emergency services (911 or local emergency number) immediately if any of the above are present
- 2. Keep the person calm and in a cool, quiet environment
- 3. If conscious, position sitting upright to ease breathing
- 4. If unconscious and breathing, place in recovery position
- 5. If not breathing, begin CPR
- 6. Do not administer beta-blockers — they worsen cocaine-related cardiac events
What to tell the dispatcher: Name the substance (cocaine or coca preparation), estimated amount and time of last use, and current symptoms. Good Samaritan laws in many jurisdictions provide legal protection for reporting drug-related emergencies.
Reversal agents: No specific reversal agent for cocaine toxicity exists. If fentanyl contamination is suspected and opioid overdose signs are present (slowed or stopped breathing, pinpoint pupils, blue lips), administer naloxone immediately.
Legal Status[edit]
Coca leaf and cocaine are controlled under international treaty in virtually all jurisdictions. The 1961 UN Single Convention places both the plant and its primary alkaloid on Schedule I — an unusual arrangement, since most scheduled plants are only controlled at the alkaloid level. In the United States, cocaine is a Schedule II controlled substance with narrow medical approval as a topical nasal anesthetic.[27] Bolivia and Peru maintain legal frameworks permitting traditional coca leaf chewing and tea consumption. Colombia — the world's largest producing country — prohibits cultivation and trafficking.[28] Argentina allows coca leaf and tea for cultural use in northern provinces. The UK classifies both cocaine and coca leaf as Class A, with maximum penalties of life imprisonment for supply.[29] Bolivia's 2013 reaccession to the 1961 Convention included an explicit reservation for traditional coca use — the only formal treaty-level exception currently in force.
Coca leaf chewing and tea consumption produce positive urine drug tests for benzoylecgonine. Standard workplace tests detect metabolites for approximately 2–4 days in most individuals. Sensitive assays using a 5 ng/mL cutoff extend the detection window to 17–22 days.[30][31]
Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information.
Preparations[edit]
Coca leaf chewing (traditional)
Coca leaf chewing is the oldest and mildest preparation. Fresh or dried leaves (20–60 g per session) are placed in the cheek with an alkaline additive — calcium hydroxide, sodium bicarbonate, or llipta (plant ash) — which raises buccal pH and promotes cocaine absorption.[9] Onset occurs over 15–45 minutes, peaking at 60–90 minutes, with a total duration of 2–4 hours. The effect profile is mild sustained alertness, appetite suppression, and gentle analgesia. Drug accumulation from repeated chewing is unlikely given the slow absorption rate.[12]
Coca tea (mate de coca)
Coca tea is prepared by steeping dried coca leaves in hot water for 5–15 minutes. Onset is 30–60 minutes, with effects lasting 2–4 hours. Oral bioavailability is approximately 32–45%.[13] The experience is comparable to leaf chewing — mild stimulation and alertness — though absorption occurs via the gastrointestinal tract rather than the buccal mucosa. Coca tea is legal and widely consumed in Bolivia, Peru, and parts of Argentina.
Cocaine hydrochloride (intranasal)
Intranasal cocaine (insufflation of cocaine hydrochloride powder) produces onset in 3–5 minutes, peak effects at 15–30 minutes, and duration of 45–90 minutes. Bioavailability is approximately 60–75%.[12] The experience is markedly more intense than leaf preparations: strong euphoria, heightened confidence, talkativeness, and a pronounced crash that drives redosing. Nasal mucosal damage occurs with repeated use.
Smoked cocaine (freebase / crack)
Smoked cocaine (freebase or crack) produces the fastest onset of any non-intravenous preparation — under one minute — with peak effects at 3–5 minutes and total duration of only 10–20 minutes. Bioavailability is approximately 70–80%. The extreme speed of onset and brevity of effect produce the most intense euphoria and the strongest drive toward compulsive redosing. Pulmonary toxicity, including "crack lung" syndrome, is specific to this preparation.[14]
Intravenous cocaine
Intravenous cocaine produces onset within seconds, peaking at 1–2 minutes, with duration of 20–40 minutes and 100% bioavailability. This route carries the highest risk of acute cardiovascular events and introduces infection risk from injection practices. Compulsive redosing frequency is comparable to smoked cocaine.
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Critical
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamines
Toxicity
Cocaine intoxication is the most frequent cause of drug-related death reported by US medical examiners.[15] No formal human LD50 exists. Lethal blood concentrations typically exceed 1 mg/L, though deaths have occurred at lower levels in the presence of cardiac conditions or co-ingested substances.safety citation needed
Cardiovascular complications represent the most clinically significant toxicity across all preparations.[6][2][16] Frequent cocaine users face a 7-fold higher risk of myocardial infarction. Mechanisms include coronary artery vasospasm, accelerated atherosclerosis, thrombus formation, and QT prolongation via sodium channel blockade. Arrhythmias — including ventricular fibrillation and sudden cardiac death — are mediated by sodium channel blockade and catecholamine surge. Chronic use produces dilated cardiomyopathy, myocarditis, and left ventricular hypertrophy.
Norcocaine, the CYP3A4-generated metabolite, is hepatotoxic. Documented pathology includes perivenular necrosis and microvesicular fatty change.[17] Multi-organ failure involving rhabdomyolysis, acute kidney injury, and hepatic ischemia has been documented as cocaine-induced C-KLM syndrome.[18]
Smoked cocaine carries preparation-specific pulmonary risk. "Crack lung" syndrome presents as acute respiratory distress with fever, hemoptysis, and diffuse alveolar hemorrhage within 48 hours of inhalation.[14] Both ischemic and hemorrhagic stroke are documented; cocaine is a recognized independent stroke risk factor. Reversible cerebral vasoconstriction syndrome has been reported even following coca leaf tea at high altitude.[19]
Contaminant and adulterant risk: Levamisole, a veterinary anthelmintic, contaminates an estimated 69–80% of illicit cocaine in the United States.[7][20] Clinical consequences include agranulocytosis with life-threatening infections, ANCA-associated vasculitis, multifocal leukoencephalopathy, and acquired protein S deficiency. Additional adulterants include local anesthetics (procaine, benzocaine, lidocaine) and, increasingly, fentanyl — which introduces opioid overdose risk toxicologically distinct from cocaine effects.
Coca leaf products sold in Andean countries carry lower adulterant risk than illicit refined cocaine, but no ISO/IEC-accredited third-party testing programs for commercial coca leaf products have been identified.citation needed
Psychological Risks
Cocaine-induced psychosis is characterized by paranoid delusions, visual and auditory hallucinations, and paranoia. Prevalence reaches as high as 86.5% in some clinical populations.[21] Risk factors include high cumulative dose, lifetime duration of use, smoked or intravenous route, cannabis co-use, ADHD comorbidity, and male sex.[21]
Sensitization rather than tolerance occurs for psychosis risk — repeated exposure progressively lowers the threshold for psychotic symptoms. Anxiety, paranoia, panic reactions, and agitation occur dose-dependently across all preparations. Grandiosity, impaired judgment, and compulsive redosing are characteristic at higher doses, particularly with smoked and intravenous preparations.
Tolerance & Dependence
Tolerance develops rapidly to cocaine's euphoriant effects. Paradoxically, sensitization occurs for psychomotor activation and psychosis risk with prolonged use. This differential neuroadaptation underlies escalating psychiatric danger alongside diminishing euphoria.
Dependence is primarily psychological, driven by mesolimbic dopamine reinforcement. Physical dependence is present but less prominent than with opioids or alcohol. Withdrawal follows a three-phase pattern[22]:
- Phase 1 — Crash (hours to 4 days): dysphoria, fatigue, hypersomnia with REM rebound effect, appetite enhancement, temporarily reduced craving.
- Phase 2 — Withdrawal (1–10 weeks): anhedonia, anxiety, sleep disturbance, intense cue-triggered cravings; highest relapse risk period.
- Phase 3 — Extinction (months to years): Gradual normalization; intermittent cue-triggered cravings persist.[22]
Recovery resources, crisis lines, and support pathways → View all
Drug Interactions
Ethanol (alcohol): The most clinically significant interaction. Hepatic enzymes catalyze transesterification of cocaine with ethanol to form cocaethylene, a metabolite more toxic than cocaine with a longer duration of action.[23][24][25] Cocaethylene yield varies by route: oral (34%) > intravenous (24%) > smoked (18%).[23]
Beta-adrenergic blockers: Contraindicated. Cocaine's alpha-adrenergic effects become unopposed when beta receptors are blocked, producing severe hypertension and coronary vasospasm.
MAO inhibitors: Theoretical risk of hypertensive crisis and serotonin syndrome via amplified monoamine activity. safety citation needed
CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): May increase parent cocaine plasma levels by reducing clearance while decreasing norcocaine formation.[11] safety citation needed
Tricyclic antidepressants: Additive cardiovascular toxicity via combined sodium channel blockade and norepinephrine reuptake inhibitor. safety citation needed
Contraindications
Pregnancy: Absolute contraindication. Cocaine use in pregnancy is associated with placental abruption, adverse neonatal outcomes, and fetal CNS development effects.[26]
Cardiovascular disease: Absolute contraindication for all preparations. Pre-existing cardiac conditions dramatically elevate myocardial infarction and sudden death risk.[6]
Hepatic impairment: Relative contraindication — impaired cocaine and norcocaine metabolism increases toxicity duration and severity.
Concurrent beta-blocker therapy: Absolute contraindication — unopposed alpha stimulation produces severe hypertension and coronary vasospasm.
Concurrent MAOI or tricyclic antidepressant therapy: Relative contraindication due to additive cardiovascular and serotonergic risk.
Psychiatric vulnerability: Relative contraindication. Schizophrenia spectrum disorders and psychosis risk are amplified by cocaine use.[21]
Pediatric and neonatal exposure: Prenatal cocaine exposure is associated with functional brain connectivity alterations in neonates.[26]
Harm Reduction[edit]
Forms & Identification
Lab testing is the only reliable method for determining the purity and composition of refined cocaine products. The illicit cocaine supply is extensively adulterated — levamisole alone contaminates the majority of US cocaine, and fentanyl contamination is increasingly common. Fentanyl test strips can detect fentanyl in cocaine samples but do not identify all synthetic opioid analogs. Reagent testing (Scott/cobalt thiocyanate) confirms the presence of cocaine but cannot quantify purity or identify all adulterants.
For coca leaf products purchased in Andean countries, adulterant risk is substantially lower, but standardized potency testing is unavailable. Alkaloid content varies across batches and cultivars — dose conservatively when switching sources.
Guidelines
- Start with the lowest effective amount and wait for full onset before considering redosing — onset varies dramatically by preparation (leaf chewing: 15–45 min; intranasal: 3–5 min)
- Pre-measure amounts before a session to limit compulsive redosing; the rapid offset of smoked and intranasal cocaine drives repeated use
- Test all refined cocaine products with fentanyl test strips before use
- Use in the presence of others who can recognize and respond to medical emergencies
- Stay hydrated and eat before use — cocaine suppresses appetite and masks dehydration
- Monitor heart rate; stop immediately and seek medical attention if chest pain, palpitations, or difficulty breathing occur
- Alternate nostrils and rinse with saline after intranasal use to reduce mucosal damage
- Avoid binge patterns; set a firm time limit for sessions
Set & Setting
The setting in which cocaine is used significantly influences risk. Social environments that normalize compulsive redosing — common with intranasal and smoked preparations — amplify dependence risk. Using alone increases the danger of unwitnessed cardiac emergencies or psychotic episodes.
A sober companion who can recognize cardiac distress or psychotic symptoms and call emergency services reduces acute mortality risk. For traditional coca leaf preparations, risk is substantially lower but not zero — reversible cerebral vasoconstriction syndrome has been reported with coca tea at high altitude.
Aftercare & integration. The post-cocaine crash typically involves dysphoria, fatigue, and appetite enhancement. For intranasal and smoked preparations, the crash can begin within minutes of last use and persist for hours to days depending on session length and cumulative dose.
Prioritize sleep, hydration, and nutrition during the crash period. Hypersomnia is expected and should not be resisted. Avoid using other stimulants to counteract post-cocaine fatigue — this extends recovery time and increases cardiovascular strain. For regular users, the withdrawal period (1–10 weeks) involves anhedonia, anxiety, and intense cue-triggered cravings. Identifying and avoiding environmental cues associated with prior use reduces relapse risk during this vulnerable window.
Recovery & Support
No FDA-approved pharmacotherapy for cocaine use disorder exists as of 2026. Evidence-supported treatments include cognitive behavioral therapy (CBT), contingency management (CM), and integrated treatment of comorbid psychiatric conditions.
For individuals seeking to reduce or stop cocaine use:
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7 referral service)
- Cocaine Anonymous: peer-support fellowship modeled on the 12-step framework
- Outpatient CBT and contingency management programs are available through most addiction treatment centers
Abrupt cessation of cocaine is medically safe, though psychologically difficult. The highest relapse risk occurs during weeks 1–10 after last use, when cue-triggered cravings are most intense. Professional support during this period significantly improves outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain, pressure, or tightness
- Irregular or racing heartbeat
- Difficulty breathing
- Severe paranoia, hallucinations, or psychotic behavior
- Seizures or loss of consciousness
- Blue lips or extremities
- Hyperthermia (hot, dry skin)
Immediate steps:
- 1. Call emergency services (911 or local emergency number) immediately if any of the above are present
- 2. Keep the person calm and in a cool, quiet environment
- 3. If conscious, position sitting upright to ease breathing
- 4. If unconscious and breathing, place in recovery position
- 5. If not breathing, begin CPR
- 6. Do not administer beta-blockers — they worsen cocaine-related cardiac events
What to tell the dispatcher: Name the substance (cocaine or coca preparation), estimated amount and time of last use, and current symptoms. Good Samaritan laws in many jurisdictions provide legal protection for reporting drug-related emergencies.
Reversal agents: No specific reversal agent for cocaine toxicity exists. If fentanyl contamination is suspected and opioid overdose signs are present (slowed or stopped breathing, pinpoint pupils, blue lips), administer naloxone immediately.
Legal Status[edit]
Coca leaf and cocaine are controlled under international treaty and domestic legislation in virtually all jurisdictions. The 1961 UN Single Convention on Narcotic Drugs places both coca leaf and cocaine on Schedule I — unlike some psychoactive plants where only the isolated alkaloid is scheduled, coca leaf itself is explicitly controlled alongside its primary alkaloid. Bolivia and Peru maintain legal frameworks permitting traditional coca leaf consumption, while refined cocaine is universally prohibited outside narrow medical applications. In the United States, cocaine hydrochloride retains limited medical approval as a topical nasal anesthetic.[27]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule I (1961 Single Convention) | Coca leaf and cocaine both Schedule I; 1988 Convention reinforces precursor controls |
| United States (federal) | Schedule II (Controlled Substances Act) | Cocaine HCl and coca leaf both Schedule II; Goprelto (2017) and Numbrino (2020) approved as topical nasal anesthetics[27] |
| Bolivia | Legal for traditional use | 22,000 ha legally authorized cultivation; coca tea and chewing permitted; reacceded to 1961 Convention in 2013 with reservation for traditional use; actual cultivation ~34,000 ha in 2024[28] |
| Peru | Legal for traditional use | ~6 million traditional consumers; ~22,000 ha legal cultivation authorized by DEVIDA; coca tea, chewing, and certain food products legal |
| Colombia | Illegal (cultivation and trafficking) | Largest producing country (~253,000 ha, 61% of global cultivation in 2023); criminal penalties for cultivation and trafficking[28] |
| Argentina | Legal for traditional use (coca leaf/tea) | Coca leaf and tea legal for cultural use in northern provinces; cocaine possession and sale illegal |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum 7 years imprisonment for possession; life imprisonment for supply; coca leaf also controlled[29] |
| European Union | Schedule I equivalent (member state laws) | Cocaine controlled in all EU member states; second most commonly used illicit drug in Europe after cannabis |
| Australia | Schedule 8 (Poisons Standard) | Prescription-only with very limited medical use; ACT enacted partial decriminalization of small amounts in October 2023[29] |
Treaty and detection considerations
Bolivia's 2013 reservation represents the only formal treaty-level exception for traditional coca leaf use. The dual scheduling of both plant material and isolated alkaloid under the 1961 Convention is unusual among psychoactive plants — psilocybin mushrooms, for example, escape explicit plant-level scheduling in many jurisdictions while the alkaloid itself is controlled. The 2025 WHO Expert Committee critical review recommended maintaining this classification while acknowledging the low public health risk of traditional consumption.[5]
Coca leaf chewing and tea consumption produce positive immunoassay urine drug tests for benzoylecgonine, cocaine's primary urinary metabolite. Standard workplace drug tests (100–300 ng/mL cutoff) detect metabolites for approximately 2–4 days after last use in most individuals. With sensitive assays using a 5 ng/mL cutoff, detection windows extend to 17–22 days.[30][31]
Frequently asked questions
What is Coca?
Coca is a stimulant plant of the family Erythroxylaceae, native to the western Andes, containing the tropane alkaloid cocaine. Preparations range from traditional leaf chewing and tea to refined cocaine hydrochloride; effects and risk vary dramatically by preparation method.
What are dangerous combinations with Coca?
The highest-severity documented interactions for Coca: Ibogaine (Lethal), Opioids (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Coca addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Coca: tolerance builds rapid; cross-tolerance develops with amphetamines. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcHeal DJ, Gosden J, Smith SL (2014) Dopamine reuptake transporter (DAT) 'inverse agonism' — a novel hypothesis to explain the enigmatic pharmacology of cocaine — Neuropharmacology doi:10.1016/j.neuropharm.2014.06.012
- [2] ^abcdRestrepo DA, Saenz E, Jara-Muñoz OA, Calixto-Botía IF, Rodríguez-Suárez S, Zuleta P, Chavez BG, Sanchez JA, D'Auria JC (2019) Erythroxylum in Focus: An Interdisciplinary Review of an Overlooked Genus — Molecules doi:10.3390/molecules24203788
- [3]
- [4] ^abcLucyk SN (2022) Acute Cardiovascular Toxicity of Cocaine — The Canadian Journal of Cardiology doi:10.1016/j.cjca.2022.05.003
- [5] ^abBuchanan JA, Lavonas EJ (2012) Agranulocytosis and other consequences due to use of illicit cocaine contaminated with levamisole — Current Opinion in Hematology doi:10.1097/moh.0b013e32834da9ef
- [6] ^abSinclair JM, Kalk NJ, Kaar SJ, et al. (2026) Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology — Journal of psychopharmacology doi:10.1177/02698811251399593
references
- [1] ^abcdHeal DJ, Gosden J, Smith SL (2014) Dopamine reuptake transporter (DAT) 'inverse agonism' — a novel hypothesis to explain the enigmatic pharmacology of cocaine — Neuropharmacology doi:10.1016/j.neuropharm.2014.06.012
- [2] ^abcdPhillips K, Luk A, Soor GS, Abraham JR, Leong S, Butany J (2009) Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options — American journal of cardiovascular drugs doi:10.2165/00129784-200909030-00005
- [3]
- [4] ^abcTsuchiya H (2017) Anesthetic Agents of Plant Origin: A Review of Phytochemicals with Anesthetic Activity — Molecules doi:10.3390/molecules22081369
- [5]
- [6] ^abcLucyk SN (2022) Acute Cardiovascular Toxicity of Cocaine — The Canadian Journal of Cardiology doi:10.1016/j.cjca.2022.05.003